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1. Introduction 
The use of autologous skin grafts comprises a well established method of reconstruction in 
large areas involving partial thickness defects. Additionally, when skin availability is 
limited due to associated trauma or injury (e.g. burns) the use of  homologous skin grafts 
from a compatible donor appears to be a valid alternative. The effort to maximize 
effectiveness of skin grafting in terms of increasing graft take, protecting viability, reducing 
full healing time and achieving improved postoperative outcomes without impairing 
function has also been constant especially in cases of impaired general condition.  
Human recombinant erythropoietin (rHuEPO) is a glycoprotein with primarily a 
hemopoietic role due to the inhibition of precursor erythrocytes and the promotion of their 
proliferation. Its genetic expression is being regulated by hypoxia. It is primarily 
synthesized by the fetal kidneys and liver and by the adult kidneys (Paschos et al. 2008). 
The biological activity of rHuEPO is promoted by its interaction with the cell surface 
erythropoietin receptor (EPOR) (Brines and Ceramic 2008) which is a type I cytokine 
expressed by precursor erythrocytes as well as in other non hemopoietic systems such as the 
central and the peripheral nervous system in response to trauma (Galeano et al. 2004), in 
cardiac muscle cells, vascular endothelial smooth muscle cells and in subcutaneous mast 
cells with potent anti-ischaemic action (Brines and Ceramic, 2008; Galeano et al. , 2004).  
Current research has focused on its non-hemopoietic role. Many studies report the local 
production of erythropoietin (EPO) in response to trauma prior to the local concentration of 
pre-inflammatory cytokines and EPO acting antagonistically to them by reducing edema, 
inhibiting cellular apoptosis, promoting neovascularization by enhancing endothelial cell 
mitosis and promoting wound healing (Paschos et al. 2008). 
Since endogenous local EPO production is inadequate, it has been shown that the exogenous 
administration of rHuEPO enhanced wound healing and revascularization in experimental 
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studies on healthy rats, rats with genetically induced diabetes mellitus and rats with burn 
injuries (Galeano 2006). In clinical studies including human subjects, the wound healing 
promoting properties of rHuEPO have been reported following Ǆ-knife for brain surgery 
and recently in patients who underwent destruction osteogenesis (Mihmanli et al. 2009) 
Vascular endothelial growth factor (VEGF) comprises a heparin-binding, dimeric 
glycoprotein which initiates the proliferation and migration of endothelial cells to 
participate in the development of new vascular lumens, and increases the penetration and 
extravasation of plasma macromolecules (Hom et al., 2005; Paschos et al., 2008 ). VEGF 
receptors are found in endothelial cells and are expressed under conditions of hypoxia and 
following endothelial damage. Two  high-affinity endothelial cell receptors, KDR/Flk-1 and 
flt-1 mediate VEGF effects on tissue physiology (Lantieri et al. 1998) 
VEGF has been shown to participate in wound healing enhancement, embryo development, 
growth of certain solid tumors, and ascites formation (Isogai et al., 2006; Schultze-Mosgau et 
al., 2003). In this study, the immunohistochemical detection of VEGF expression is used as a 
method of skin graft take evaluation.  
Tacrolimus (FK-506), has recently been established as a valid immunosuppressant and 
comprises a well-known calcineurin (a serine/threonine phosphatise) inhibitor. It has been 
shown that FK-506 inhibits TGF-ǃ  induced VEGF production by antagonizing calcineurin 
which leads to the attenuation of the activation and translocation of the nuclear factor that 
activates T-cells (nft) (Mori et al 1997). FK-506 also inhibits: a) interleukin-2 induced 
interleukin-5 production by CD4+ T cells and b) T-cells proliferation stimulated by 
interleukin-2 and interleukin-7 (Mori et al 1997). Confirmation was provided by similar 
studies which showed that rapamycin, another immunosuppressant which does not inhibit 
calcineurin, did not have any effect on TGF-ǃ  induced VEGF production while cyclosporine 
A, which is also a calcineurin inhibitor, resulted in reduction of VEGF production (Marumo 
et al. 1995). The action of FK-506 is mediated by immunophilins, a class of proteins which 
bind to immunosuppressive drugs, giving to FK-506 the ability to interact with calcineurin 
and to interfere with its access and dephosphorylation of various substrates. The primary 
immunophilin was shown to be FKBP 13 which is localized to the endoplasmic reticulum 
lumen, where processing and presentation of antigen in the immune system are thought to 
take place (Nigam et al. 1993). The liver and the intestinal mucosa are the main sites of FK-
506 metabolism by the cytochrome P4503A4 enzyme. Subsequently, FK-506 is eliminated 
through biliary excretion. (Lampen et al., 1995; Nakazawa et al., 1998; Plosker & Foster, 
2000). FK-506 has been widely used systemically, maintaining a profile of safety during the 
long-term experience with the drug. Most side effects appear to be related to whole-blood 
concentrations and refer to nephrotoxicity, cardiovascular toxicity, metabolic and 
neurotoxicity. However, almost all of the reports of FK-506  toxicity are derived from its use 
in solid-organ transplantation, in which much higher doses are used compared to those for 
skin transplantation (Mayer et al., 1997; Pirsch et al. 1997). The aim of this animal study is to 
investigate the effect of human recombinant erythropoietin (rHuEPO) and tacrolimus (FK-
506) on autologous and homologous full thickness skin grafts in an experimental research 
design including Wistar rats. 
2. Methods and material 
Thirty adult inbred female Wistar rats (n=30), with weights ranging from 220 to 300 gr, were 
selected for this study. Two control and 3 experimental groups were formed, each consisting 
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of 6 subjects. This experimental study followed the National Research Council’s Guide for 
the Care and Use of Laboratory Animals and was approved by the National Bioethics 
Committee. This study used the minimum number of animals needed in order to establish a 
valid conclusion and statement regarding the specific subject. All necessary refinements and 
design methods have been performed and planned according to accredited established 
protocols. All surgical procedures were performed under general anesthesia with the use of 
ketamine hydrochloride (80 mg/kg intramuscularly) and xylazine (2 mg/kg 
intramuscularly). 
After induction of general anesthesia the surgical site was shaved and prepped with 
povidone iodine and chlorhexidine solution. The animals were covered with sterile surgical 
drapes with only the operative site exposed. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Preoperative design of the FTSG on the back of the subject 
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Fig. 2. Dissection and harvesting of the FTSG and then rotation of the FTSG on the wound 
bed by 180o so as the previously caudal edge becomes rostral and the donor site can be used 
as the recipient site 
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Fig. 3. Cleaned wound area and dressing application on the FTSG 
A full thickness skin graft was harvested from the area between the two scapula bones on 
the dorsum of each rat. The skin graft was elliptical in shape, with a long diameter of 2 cm 
and a small diameter of 1 cm (Figure 1). During harvesting, the panniculus layer was 
carefully removed from the bed of the skin graft and recipient site. The skin graft was kept 
in phosphate-buffered saline before being transferred to the recipient site. In this 
experimental model, each skin graft was repositioned in the same area from which it was 
harvested after being rotated by 180 degrees in the vertical axis, so as the severed vascular 
axons in the skin graft remain misaligned to the vascular axons of the recipient bed. In this 
way each donor site also serves as a recipient site since revascularization and new vascular 
connections between skin graft and recipient bed are still required due to the preserved 
vascular misalignment in the new graft position. When a homologous FTSG was required, 
animals underwent surgery in pairs and a FTSG was harvested in the aforementioned way 
from each animal and it was then transplanted into the donor site of the other after being 
similarly rotated  by 180 degrees (see subject groups below). 
The location of the recipient bed is conveniently situated between the scapular bones, 
unreachable by the rats and well fixated on a minimally mobile area causing negligible 
irritation to the rats. No animal involved in this project was subjected to discomfort, pain, or 
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distress. Any such discomfort, pain, or distress was alleviated with the appropriate 
approved medication (Figure 1-3). Nylon 5-0 non-absorbable sutures were invariably used. 
The animals were placed in a warm environment with the aid of heating lamps and were 
continuously monitored. Pain management was carried out with the use of Buprenorphine 
at 0.05-0.10 mg/Kg, SC, and then twice daily. The animals were observed for their pattern of 
breathing, alertness, ability for food and drink uptake. After surgery rats were carefully 
observed for dehydration and diarrhea. Rats were kept separately in their housing cages 
which were standard filter top secured cages.  
The animals were randomized into the following groups according to the treatment that was 
used:  
Group A (First control group, n=6): An autologous FTSG was harvested and repositioned. 
Local infiltration with water for injection was also performed as a control. 
Group B (Second control group, n=6): Animals underwent surgery in pairs. Consequently 
there were 3 pairs in this group. A homologous FTSG was harvested from each animal of 
each pair and transplanted into the donor site of the other. FK506 (tacrolimus) was 
administered systematically to prevent rejection. Local infiltration with water for injection 
was also performed as a control. 
Group a (experimental, n=6): An autologous FTSG was harvested and repositioned. Local 
infiltration with rHuEPO was performed. 
Group b (experimental, n=6): Animals underwent surgery in pairs as in group B, forming a 
total of 3 pairs. A homologous FTSG was harvested from each animal and it was 
transplanted into the donor site of the other  while FK506 (tacrolimus) was administered 
systematically (local infiltration) to prevent immunologic response. Local infiltration with 
rHuEPO was performed. 
Group c (experimental, n=6): An autologous FTSG was harvested and repositioned and local 
infiltration with FK506 was performed. Table 1 summarizes the details regarding each 
animal group. 
 
Group Type 
Number of 
subjects 
FTSG FK506 rHuEPO wfi 
A control 6 autologous no no yes 
B control 6 homologous 
for 
immunosuppression
no yes 
a experimental 6 autologous no factor no 
b experimental 6 homologous 
for 
immunosuppression
factor no 
c experimental 6 autologous factor no no 
Table 1. The animal groups in the study. FTSG: full thickness skin graft,  for 
immunosuppression: FK506 is used in order to prevent rejection, not as tested factor, factor: 
FK506 or rHuEPO are used as local infusion around the recipient bed and their effect on 
graft viability and healing is tested, wfi: water for injection used for local infiltration as a 
placebo, when one of the previously mentioned factors were not used 
FK-506 (Fujisawa USA, Inc.) was dissolved in 80% ethanol and 20% cremaphor to create a 
stock solution with a concentration of 10 mg/ml. This stock was then diluted with 75% 
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propylene glycol and 25% water to a final concentration of 0.5 mg/ml. The diluted solution 
was replaced every 3 days.  
In groups B and b, FK-506 was subcutaneously administered daily at a dose of 2mg/Kg. The 
use of FK-506 either as a systematic immunosuppressant (groups B and b) or as a local agent 
(group c) always involved local, subcutaneous infiltration. In groups a and b, 400UI/kg in a 
100μL solution of rHuEPO were subcutaneously administered, daily. Local infiltration of 
agents was invariably performed around and under the recipient bed.  
The effect of FK-506 and rHuEPO administration in the aforementioned experimental 
groups was investigated. The investigation consisted of the clinical, histological and 
immunohistochemical evaluation of the grafts and their viability-take on the 10th post 
grafting day. All subjects were euthanized on the 10th post grafting day by prolonged 
inhalation in a closed diethyl-ether inhalation chamber.  
Skin graft take area and viability were assessed using digital photographs and manual 
measurements. The photographs were processed by digital image surface area analysis 
software (Pixcavator Image Analysis Software 2.3). Specimens of autologous and 
homologous skin grafts were then harvested together with a marginal recipient bed skin, 
along the perimeter of the graft for histological examination and immunohistochemistry. 
The formalin fixed, paraffin embedded tissue sections were treated with hematoxylin-eosin 
stain as well as by two antibodies. Standard procedures as recommended by the 
manufacturer were performed. 
The antibodies used in our study were: 
Monoclonal Mouse Anti-Human Vascular Endothelial Growth Factor, Clone VG1, isotype: 
IgG1, kappa antibody was used to label the VEGF-121, VEGF-165, and VEGF-189 isoforms 
of vascular endothelial growth factor (VEGF) Clone VG1. 
Monoclonal Mouse Anti-Human CD31, Endothelial Cell, Clone JC70A, isotype: IgG1, kappa, 
(Dako A/S, Glostrup 
Denmark Autostainer/Autostainer Plus) antibody was used to label endothelial cells of 
newly formed vessels to determine angiogenesis. 
Histology findings were evaluated for vascular presence and endothelial condition, 
lymphocytic infiltration, dermal/epidermal interphase reaction (spongiosis, incomplete, 
complete epidermal separation) and necrosis. More specifically, due to the relatively 
variable macroscopic presentation of homologous graft rejection, histology findings and 
criteria were solely used to describe and categorize potential rejection according to the 
established method of Tatsuya et al (1997) which includes the following three grades:  
Grade 1: intraepidermal blister formation, 
Grade 2: incomplete epidermal separation from the dermis; 
Grade 3: complete epidermal separation from the dermis.  
Immunochemistry analysis aimed at demonstrating the degree of angiogenesis in the skin 
grafts as a direct sign of vascular network rearrangement and development, viability and 
effective graft take.  
Manual measurement and clinical assessment of graft take was performed using light 
microscopy and corresponded adequately with the digital image analysis.  
Spleens were harvested and subjected to the mixed lymphocyte reaction, to assess the 
degree of immunosuppression. Liver and kidneys were also harvested and examined for 
signs of potential hepato- and nephrotoxicity. 
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3. Statistical analysis 
Areas of graft take comprise numeric data which are presented with approximation of 
two decimal digits. Means are presented  ±SD where applicable, and the t test for 
independent samples has been used for statistical analysis of the results. SPSS 17.0 (IBM 
Corporation Somers, NY 10589) was used. Statistical significance was considered for 
p<0.05. 
4. Results 
Clinical results were classified according to the mean area of inadequate graft take – graft 
necrosis (N). In control group A   N=40.98 mm2, in control group B N=71.2 ± 4.67mm2, in 
experimental group a N= 15.22 ± 4.76 mm2 in experimental group b N= 29.2± 4.70 mm2, in 
experimental group c N=46.52 ± 4.60 mm2. Manual measurements corresponded well with 
the aforementioned digital image analysis measurements.  The corresponding percentages 
(over the total area of each graft which was 20 x 10 mm2= 200 mm2) of mean graft necrotic 
areas were: group A: 20.49%, group B: 35.6%, group a: 7.6%, group b: 14.6%, group c: 23.26% 
(p<0.001 in all group comparisons: A-a, B-b and A-c) (Figures 4-9). 
Histological findings using hematoxylin-eosin stain showed the differences in graft 
revascularization and take among groups (10th post-grafting day) (Figures 10-19) 
Immunohistochemistry resulted in significant observations regarding graft 
revascularization in the each group (Figures 20-27). 
Clinical, histological and immunohistochemical findings consistently show the resulting 
quality of graft take and degree of revascularization among the various groups: graft take in 
group a>group b> group A> group c> group B. 
No signs of hepato- and nephro-toxicity were found.   
 
 
Fig. 4. Mean inadequate graft take-necrosis  percentage per group. A, B, a, b and c 
correspond to animal groups 
www.intechopen.com
The Effect of Human Recombinant Erythropoietin (rHuEPO) and Tacrolimus (FK506) in 
Autologous and Homologous Full Thickness Skin Graft (FTSG) Take and Viability in a Rat Model 205 
 
 
Fig. 5. Group A macroscopic presentation. Mild peripheral necrosis, good overall take 
 
 
Fig. 6. Group a macroscopic presentation. Full graft take, no signs of necrosis, excellent graft 
viability 
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Fig. 7. Group B macroscopic presentation. Considerable peripheral graft rejection. Central 
graft take and viability 
 
 
Fig. 8. Group b macroscopic presentation. Minimal peripheral rejection and nearly complete 
graft take. 
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Fig. 9. Group c macroscopic presentation. Partial graft necrosis, not uniform graft take 
compared to control group A. 
Groups A-a 
 
Fig. 10. Formalin fixed, paraffin embedded FTSG x50 in group A. Normal graft take with 
intermediate inflammatory inflammation demonstrating FTSG take without the use of 
exogenous active factors. 
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Fig. 11. Formalin fixed, paraffin embedded autologous FTSG x200 in group A. Vascular 
lumens with erythrocytes (v), polymorphonuclear cells(p),  lymphocytes (l)  and other 
inflammatory cell intermediate concentrations are also shown. The number of vessels is 
indicative of the quality of graft take and viability 
 
 
Fig. 12. Formalin fixed paraffin embedded autologous FTSG x50 in group a. Higher vessel 
concentration, more uniform and higher epidermal layer (double arrow line), less 
inflammatory infiltration than in control group A 
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Fig. 13. Formalin fixed, paraffin embedded autologous FTSG x200 in group a. Vascular 
lumens with erythrocytes (v), polymorphonuclear cells(p),  lymphocytes (l)  and other 
inflammatory cell concentrations are also shown. Note the increased number of vessels and 
the milder inflammatory response which  are indicative of better quality of graft take and 
viability than in the control group 
 
s  b 
Fig. 14. Homologous FTSG x50 in group B. Increased intraepidermal blisters (b), 
dermoepidermal lack of cohesion (s) and increased inflammatory infiltration compatible 
with grade 2-3 of rejection according to Tatsuya et al (1997).  
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Groups B-b 
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Fig. 15. Formalin fixed, paraffin embedded homologous FTSG x200 in group B. 
Inflammatory response and mild revascularization compatible with the initial stages of 
rejection, impairing the ongoing course of graft revascularization (v) and take. Inflammatory 
cells include large eosinophils concentrations (e) characteristic of the aforementioned 
response type. 
 
 b 
Fig. 16. Formalin fixed, paraffin embedded homologous FTSG x50 in group b. 
Intraepidermal blisters (b) but lack of partial dermoepidermal separation. Better quality of 
graft take and minimal rejection response than in control group B. 
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Fig. 17. Formalin fixed, paraffin embedded homologous FTSG x200 in group b. Inflammatory 
response with concentrations of eosinophils (e), lymphocytes (l) and polymorphonuclear cells 
(p) but also nearly unimpaired revascularization (v) demonstrating a considerably better 
quality of graft take and milder rejection response than in control group B. 
Group c 
 
Fig. 18. Formalin fixed, paraffin embedded autologous FTSG x50 in group c. Nearly normal 
graft take with minimal inflammatory response, firm dermoepidermal cohesion but 
marginally decreased new vessels development than in control group A. 
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Fig. 19. Formalin fixed, paraffin embedded autologous FTSG x200 in group c. Nearly normal 
graft take with minimal inflammatory response and decreased revascularization compared 
to group A. 
Groups A-a 
 
Fig. 20. VEGF expression in group A, as detected by treating tissues with human VEGF 
monoclonal antibody. Low or absent stain in the normal autologous grafting group.  
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Fig. 21. VEGF expression in group a, as detected by treating tissues with human VEGF 
monoclonal antibody. Stained-activated macrophages (brown) are noted indicating an 
increase in revascularization process compared to the control group A 
 
 
 
 
 
 
Fig. 22. CD31 stained endothelial cells of newly formed vessels (copper color) in control 
group A (left) and group a (right). Notably increased angiogenesis is shown in group a 
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Groups B-b 
 
 
 
Fig. 23. VEGF expression in group B, following tissue treatment with human VEGF 
monoclonal antibody. Low or absent stain in the homologous grafting group. Blisters are 
also noted, indicative of early rejection response signs. 
 
 
 
 
 
 
Fig. 24. VEGF expression in group b after the use of VEGF monoclonal antibody. Stained-
activated macrophages (brown) are noted compared to their absence in group B tissues, 
indicative of increased angiogenesis. 
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Fig. 25. CD31 stained endothelial cells of newly formed vessels (copper color) in control 
group B (left) and group b (right). Note the absence of endothelial concentrations in group B 
and the increased angiogenesis in group b 
Groups c 
 
 
 
Fig. 26. VEGF expression in group c, after treating tissues with human VEGF monoclonal 
antibody. Minimal stain in the autologous grafts included in group c. 
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Fig. 27. CD31 stained endothelial cells of newly formed vessels in group c. Considerable 
decrease in angiogenesis compared to control group A 
5. Discussion 
Between days 3 and 8 after grafting, the transient formation of spherical protrusions in the 
graft capillaries resembling angiogenic buds is taking place in what appears to be an 
angiogenic response of the autochthonous graft capillaries (Lindenblatt et al 2010). 
Proangiogenic molecules in the recipient bed and the graft tissue were revealed by 
immunohistochemical analysis which showed that the wall of the aforementioned buds 
expressed CD31 and desmin, indicating the presence of both endothelial cells and pericytes 
(Gerhardt & Betsholtz 2003). A docking of sprouting vascular formation takes place from the 
recipient bed which connects to the aforementioned spherical protrusions of the pre-existing 
graft vessels unlike the previously suggested neovascularization theory which requires 
weeks to complete. Additionally, there is rather no vessel inosculation from the recipient 
bed to the graft as it was previously accepted but there is what appears to be a gradual 
angiogenic response leading to newly formed vascular buds (Goretsky et al., 1995; Okada 
,1986; Young et al., 1996).  
The traditional vessel inosculation theory implies vessel re-formation and lumen restoration 
of already existing vessels via direct approximation of vessels of the recipient bed and the 
ones in the graft. Since it is nearly impossible to assume that simple graft positioning leads 
to an effective number of successful graft-bed vessel couplings, the aforementioned 
angiogenetic process has been recently described. Conversely, it has also been suggested 
that pre-existing channels in the graft allow vessels from the recipient bed to invade the 
graft from the periphery replacing a considerable number of graft vessels (Capla et al. 2006) 
In order to provide the physiologic mechanism of graft take process it could be suggested 
that during the initial stages (hours) following transplantation, blood, nutrients and 
angiogenic factors cover the graft area and bed. Hypoxia along with the substrate of 
available factors creates the signal for the angiogenic response which commences at 2-3 
postgrafting days. According to our findings it was noted that the center of the graft 
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contains a higher density of vascular buds and vessels suggesting that angiogenesis begins 
there and continuous outwardly towards the periphery of the graft. It is controversial 
whether angiogenesis takes place before the 2-3td postgrafting day since there are authors 
who claim that the graft on its own has the physiologic potential to perform angiogenesis 
much earlier (Laschke et al., 2008; Shepherd et al., 2004). However, it is generally accepted 
that revascularization is a process that involves the presence of both the recipient bed and 
the graft itself since it is their interaction which leads to effective angiogenesis. Additionally, 
after the initial angiogenic response, vessels from the recipient bed gradually take over and 
invade-merge with the existing vascular infrastructure of the graft and with the newly 
formed vascular buds. Following that, endothelial cells initially migrate into the 
perivascular space creating gradually enlarging vascular lumens which in turn are covered 
by a migrating pericytes from the inner side of the vascular wall. Pericytes control and 
further organize the formation of effective vascular structure by producing VEGF and by 
signalling the end of aberrant angiogenesis where it takes place.   
Wang et al (1996) in their study including 22 Sprague-Dawley rats, used human platelet 
derived wound healing factor (HPDWF) from burn patients and porcine pituitary extract on 
the recipient bed of 6 pieces of FTSG placed 1 cm apart on the back of each rat and 
investigated their effect on wound healing. The recipient site was actually the bed of a 
previously raised dermocutaneous local flap which was subsequently re-positioned on top 
of the grafts after interposing a completely occlusive sheet between the flap and the grafts. 
They found approximately 14.4% for the HPDWF and 13.16% for the PPE group 
improvement in terms of the time needed to bridge the gaps between the FTSGs. However, 
limitations in their study are the fact that there was no account of the role of the overlying 
flap in graft wound healing despite its suggested occlusive nature by adding for example a 
control group without the flap covering technique as well as the lack of evidence regarding 
the histochemical compatibility of the used factors with the subjects and the potential 
adverse effects of their use. Additionally the study refers to autologous skin grafts only. 
Tatsuya et al (1997) found that the topical application of FK-506 on rat skin allografts may 
prolong their viability and prevent the rejection cascade phenomena. Nevertheless there was 
no attempt to further improve graft take results like in our study where the additional use of 
rHuEPO provided additional graft healing improvement in terms of lowering the 
percentage of post-grafting necrosis by 21% compared to the control group where only FK-
506 was used (35.6% vs 14.6). In our study, rHuEPO had a considerably favorable effect on 
graft take and viability by achieving 12.89% less graft necrotic area (20.49%-7.6%). 
According to Kaemmer et al. (2010) the formation of granulation tissue in soft tissue wounds  
is promoted by rHuEPO primarily under tissue hypoxia. More specifically, rHuEPO 
promotes cell migration, proliferation, myo-fibroblasts and VEGF production, solely under 
hypoxia but not under normoxia. Consequently, hypoxia in the graft tissue comprises the 
signal for the initiation of rHuEPO promoting effect on the graft healing process. 
In group b, the additional administration of rHuEPO achieved 21% smaller area of graft 
necrosis. The favorable effect of rHuEPO was shown in homologous skin grafting. New 
drugs have been developed in order to achieve prevention of the rejection process without 
causing toxicity is a goal in transplantation with calcineurin inhibitors (CNIs) comprising 
one o them. Rejection was prevented by the use of FK-506, which is a CNI, while rHuEPO 
promoted gradual healing of the graft area due to its effect on cell migration and new vessel 
formation. It could be suggested that preventing excessive inflammatory response and 
tissue rejection 'bought' the necessary time for rHuEPO to have its favorable effect in graft 
and wound healing. Additionally, it has been demonstrated that rHuEPO inhibits the 
production of pro-inflammatory cytokines by inflammatory cells, antagonizing the 
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activation of local mechanisms which trigger potential innate injury response (Strunk et al. 
2008). Thus it could be suggested that the tissue protective action of rHuEPO complemented  
indirectly the rejection preventing role of FK-506.  
Graft take and revascularization were lower in group c where FK-506 was administered in 
subjects with autologous skin grafts than in the control group A. According to Mori et al 
(1997) the explanation could be suggested to be the multiple inhibitory action of FK-506 to 
many wound healing mediator molecules, primarily to TGF-ǃ  induced VEGF, leading to 
angiogenesis impairment and consequently to graft take interference. However, it was 
shown that graft take obstruction by FK-506 is neither irreversible nor detrimental since the 
process of graft take appears to progress achieving optimum or nearly optimum levels. It 
could therefore be suggested that FK-506 creates a new equilibrium, unfavorable to graft 
revascularization, prolonging the required time for complete graft take and increasing the 
risk of impaired viability for a part of the graft tissue. Nevertheless, more studies are 
required to clarify the exact FK-506 mechanism of action in graft take and healing. 
The potential clinical investigations that the finding of this study could include are the use of 
rHuEPO in immunologically challenged patients (such as patients with extensive trauma, burn 
injuries, transplanted organs, cancer, immunocompromising infectious disease, special 
medication treatments, radioactivity injuries, hematological diseases etc) in order to promote 
or/and sustain good quality skin graft take during the course of their hospitalization or even 
permanently, as a definitive treatment. In our knowledge this is the first time rHuEPO has 
been used in conjunction with FK-506 in homologous skin grafting with favorable results.  
When it comes to the potential use of skin graft promoting factors to patients, considerations 
regarding adverse effects also concern the use of rHuEPO as its systemic administration has 
been associated with strong pro-coagulant and hemodynamic effects which are likely to lead 
to thrombotic complications especially in patients with cancer, infection, or trauma. 
Exacerbating the abnormal retinal angiogenesis in patients presenting with retinopathy and 
the tumor growth supporting effect of rHuEPO have also been reported (Bennett et al., 2008; 
Corwin et al., 2007). Nevertheless, there is not enough evidence to support any of the 
aforementioned adverse effects. Cautious use in patients with history of diabetes, heart 
disease, cancer and extensive trauma is always required. 
6. Conclusion 
Human recombinant erythropoietin promotes autologous FTSG take and viability in rats. It 
also appeared to have a favorable effect on homologous FTSG in rats, with the use of FK-506 
as an immunosuppressant. When used alone in rats with autologous skin grafts, FK-506 was 
shown to have a moderately unfavorable effect on graft take. Overall, rHuEPO was shown 
to promote graft take and viability in rats. Clinical considerations regarding both the 
favorable and the adverse effects of special factors when used in patients, require future 
studies which could provide additional insight and feedback. 
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